-
Mashup Score: 13
PFS and other outcomes with letrozole-palbociclib almost identical to chemotherapy
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 10ESMO Breast Cancer Virtual Congress 2021 | OncologyPRO - 3 year(s) ago
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
More than 300 resources from #ESMOBreast21 available on OncologyPRO to help you dive deeper into the latest #cancerresearch in #BreastCancer 👉 https://t.co/BqufyiGefu #bcsm https://t.co/f9PYJWlK5C
-
-
Mashup Score: 0
The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The differentiated TROP2-directed ADC datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer. @ABhealer108 @myESMO #ESMOBreast21 #bcsm https://t.co/vdMGlIlQSp
-
-
Mashup Score: 1
PFS and other outcomes with letrozole-palbociclib almost identical to chemotherapy
Source: www.medpagetoday.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This chemotherapy-free neoadjuvant regimen led to similar #breastcancer outcomes, reported Suzette Delaloge, MD, at #ESMOBreast21. By @CBankheadMPT. @myESMO #BCSM #onctwitter https://t.co/puSUmgRe3p
-
-
Mashup Score: 0Tailored follow-up care could benefit breast cancer survivors - 3 year(s) ago
Survivors of breast cancer differed greatly in symptom burden after the end of treatment, indicating they could benefit from personalized follow-up care, according to a study presented at ESMO Breast Cancer 2021 Virtual Congress.“Current standards of follow-up are in general the same for all breast cancer survivors. Our study underlines the importance of more tailored follow-up care,”
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
"Currently the needs of breast cancer survivors are not fully met and there is a growing demand for personalized follow-up care," says @KellyDeLigt PhD @NKI_nl https://t.co/v1UU65hKK9 #ESMOBreast21 @myESMO https://t.co/ubSfK14mmX
-
-
Mashup Score: 0Tailored follow-up care could benefit breast cancer survivors - 3 year(s) ago
Survivors of breast cancer differed greatly in symptom burden after the end of treatment, indicating they could benefit from personalized follow-up care, according to a study presented at ESMO Breast Cancer 2021 Virtual Congress.“Current standards of follow-up are in general the same for all breast cancer survivors. Our study underlines the importance of more tailored follow-up care,”
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"Currently the needs of breast cancer survivors are not fully met and there is a growing demand for personalized follow-up care," says @KellyDeLigt PhD @NKI_nl https://t.co/Isx7BrYsJS #ESMOBreast21 @myESMO https://t.co/jfrAwvnvqq
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 3 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Congratulations to everybody who presented at #ESMOBreast21 and special thanks to those who spoke with us 🙌 Missed out? Visit https://t.co/ys1d8pDAKO to catch up! 👩💻 @VJOncology @myESMO @OncoAlert #BreastCancer #BCsm #OncoAlert https://t.co/eq5NpPk5bm
-
-
Mashup Score: 0
Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@CAP_MDNY, MD, MBA, of @Respiratory_NYC discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan. @myESMO #ESMObreast21 #bcsm https://t.co/oIMCFzS5Ua
-
-
Mashup Score: 0Dr. Conte on Outcomes With 1 Year Vs 9 Weeks of Adjuvant Trastuzumab in HER2+ Breast Cancer - 3 year(s) ago
Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pier Franco Conte, MD, of Istituto Oncologico Veneto discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer. @myESMO #ESMObreast21 #bcsm https://t.co/aY4ikcdR7E
-
-
Mashup Score: 3High-Grade ILD Prevention With Trastuzumab Deruxtecan Includes Early Detection, Optimal Management in HER2+ Metastatic Breast Cancer - 3 year(s) ago
Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
High-Grade ILD Prevention With Trastuzumab Deruxtecan Includes Early Detection, Optimal Management in HER2+ Metastatic Breast Cancer @CAP_MDNY @MountSinaiNYC @myESMO #ESMOBreast21 #bcsm https://t.co/PfJQklzi5g
-
This chemotherapy-free neoadjuvant regimen led to similar #breastcancer outcomes, reported Suzette Delaloge, MD, at #ESMOBreast21. By @CBankheadMPT, @MedpageOnco. @myESMO #BCSM #onctwitter https://t.co/6BS6VdXFF5